Share

May 02, 2017; 88 (18) Editorial

Cell surface antibody–associated neurodegeneration

The case of anti-IgLON5 antibodies

Russell C. Dale, Sudarshini Ramanathan
First published April 5, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003931
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
219

Share

Article Information

vol. 88 no. 18 1688-1690
DOI: 
https://doi.org/10.1212/WNL.0000000000003931
PubMed: 
28381512
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 5, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Russell C. Dale, MRCP, PhD and
    2. Sudarshini Ramanathan, FRACP
  1. Russell C. Dale, MRCP, PhD and
    2. Scientific Advisory Boards:

    1. Queensland Children's Medical Institute Research advisory committee. Not for profit.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. received an honoraria for lecturing from Biogen Idec and Bristol-Myers-Squibb

    Editorial Boards:

    1. Editorial advisory board member of MSARD Editorial board member of Neurology: euroimmunology and Neuroinflammation Editorial board member of European Journal of aediatric Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. Biogen Idec honoraria in 2008 and Bristol-Myers-Squibb in 2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC national grant in 2011 national grant for encephalitis study NHMRC practitioner fellowship 2014-8 NHMRC project grant 2015

    Research Support, Academic Entities:

    1. Multiple Sclerosis Research Australia 2015

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Sudarshini Ramanathan, FRACP
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Sudarshini Ramanathan has received a scholarship from the National Health and Medical Research Council (Australia)and a stipend from the Petre Foundation

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute for Neuroscience and Muscle Research (R.C.D., S.R.), University of Sydney; Children's Hospital at Westmead (R.C.D.); and Westmead Hospital (S.R.), Sydney, Australia.
  1. Correspondence to Dr. Dale: Russell.dale{at}health.nsw.gov.au
View Full Text

Article usage

Article usage: April 2017 to December 2022

AbstractFullPdfSource
Apr 2017682036Highwire
May 20175375867Highwire
Jun 201754714Highwire
Jul 20175338Highwire
Aug 20174724Highwire
Sep 20173633Highwire
Oct 20173064Highwire
Nov 201726610Highwire
Dec 20171963Highwire
Jan 20182534Highwire
Feb 20182044Highwire
Mar 20183011Highwire
Apr 20182411Highwire
May 20181934Highwire
Jun 20182121Highwire
Jul 20182323Highwire
Aug 20181801Highwire
Sep 20182634Highwire
Oct 20181721Highwire
Nov 20181210Highwire
Dec 20181632Highwire
Jan 20193211Highwire
Feb 20192933Highwire
Mar 20192411Highwire
Apr 20192511Highwire
May 20192100Highwire
Jun 2019912Highwire
Jul 20192600Highwire
Aug 2019933Highwire
Sep 20191822Highwire
Oct 20192510Highwire
Nov 20191800Highwire
Dec 20191921Highwire
Jan 20202511Highwire
Feb 2020800Highwire
Mar 20201800Highwire
Apr 2020541Highwire
May 20201401Highwire
Jun 2020513Highwire
Jul 20202312Highwire
Aug 20201900Highwire
Sep 20201441Highwire
Oct 20201721Highwire
Nov 20201541Highwire
Dec 2020720Highwire
Jan 20212210Highwire
Feb 20212112Highwire
Mar 20212931Highwire
Apr 20212212Highwire
May 20212043Highwire
Jun 20211812Highwire
Jul 20211800Highwire
Aug 20212202Highwire
Sep 20212011Highwire
Oct 20211930Highwire
Nov 20212300Highwire
Dec 20211432Highwire
Jan 20222200Highwire
Feb 20222900Highwire
Mar 20223901Highwire
Apr 20221410Highwire
May 2022700Highwire
Jun 20221920Highwire
Jul 20224441Highwire
Aug 20222240Highwire
Sep 20221322Highwire
Oct 2022210Highwire
Nov 20222300Highwire
Dec 2022600Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me